Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.57 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 16/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2915303 | 0.99 | HRH3 (0.58) | HRH3PTGDR2CCR5KCNH2 | |
| SCHEMBL2915670 | 0.86 | CCR5 (0.62) | HRH3CCR5KCNH2 | |
| Hydrochloric Acid SCHEMBL2916284 | 0.85 | CCR5 (0.61) | HRH3CCR5KCNH2 | |
| SCHEMBL2909766 | 0.81 | CCR5 (0.51) | PTGDR2CCR5KCNH2 | |
| Hydrochloric Acid SCHEMBL2918113 | 0.81 | CCR5 (0.50) | PTGDR2CCR5KCNH2 | |
| SCHEMBL2914514 | 0.76 | HRH3 (0.58) | HRH3CCR5KCNH2 | |
| Hydrochloric Acid SCHEMBL2918916 | 0.75 | HRH3 (0.59) | HRH3CCR5KCNH2 | |
| SCHEMBL2910485 | 0.74 | CCR5 (0.65) | HRH3CCR5KCNH2 | |
| Hydrochloric Acid SCHEMBL2917628 | 0.74 | CCR5 (0.64) | HRH3CCR5KCNH2 | |
| SCHEMBL2916843 | 0.74 | CCR5 (0.57) | HRH3PTGDR2CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430027-B1 | NOVEL AMINOAZETIDINE, -PYRROLIDINE AND -PIPERIDINE DERIVATIVES | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-09-01 | — | — | EP | claimed |
| EP-1430027-B1 | NOVEL AMINOAZETIDINE, -PYRROLIDINE AND -PIPERIDINE DERIVATIVES | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1430027-B1 | NOVEL AMINOAZETIDINE, -PYRROLIDINE AND -PIPERIDINE DERIVATIVES | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-09-01 | — | — | EP | disclosed |
| US-6673829-B2 | TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM, THE PERIPHERAL NERVOUS SYSTEM, THE CARDIOVASCULAR SYSTEM, THE PULMONARY SYSTEM, THE GASTROINTESTINAL SYSTEM AND THE ENDOCRINOLOGICAL SYSTEM. | NOVO NORDISK A/S (DK) | 2004-01-06 | — | — | US | disclosed |
| US-20030130253-A1 | Novel aminoazetidine,-pyrrolidine and -piperidine derivatives | VTVX HOLDINGS II LLC | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130253-A1 | Novel aminoazetidine,-pyrrolidine and -piperidine derivatives | HRH3, HRH1, HRH2 | HRH3 1/4885PTGDR2 79/4885CCR5 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.